MX2021011614A - Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb. - Google Patents

Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.

Info

Publication number
MX2021011614A
MX2021011614A MX2021011614A MX2021011614A MX2021011614A MX 2021011614 A MX2021011614 A MX 2021011614A MX 2021011614 A MX2021011614 A MX 2021011614A MX 2021011614 A MX2021011614 A MX 2021011614A MX 2021011614 A MX2021011614 A MX 2021011614A
Authority
MX
Mexico
Prior art keywords
solid forms
compound
core protein
hbv
hbv core
Prior art date
Application number
MX2021011614A
Other languages
English (en)
Inventor
Jing Xiong
Xuemei Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021011614A publication Critical patent/MX2021011614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a formas sólidas novedosas del compuesto (I), (ver Fórmula), ácido 3-[(8aS)-7-[[(4S)-5-etoxicarbo nil-4-(3-fluoro-2-metil-fenil)-2-tiazol-2-il-1,4-dihidropirimidin -6-il]metil]-3-oxo-5,6,8,8a-tetrahidro-1H-imidazo[1,5-a]pirazin-2 -il]-2,2-dimetil-propanoico y las composiciones farmacéuticas que comprenden las formas sólidas del mismo divulgadas en la presente descripción, que pueden usarse como inhibidor de la cápside del VHB (o modificador alostérico de la proteína del núcleo del VHB), o para el tratamiento o la profilaxis de una enfermedad vírica en un paciente relacionada con la infección por VHB o una enfermedad provocada por la infección por VHB.
MX2021011614A 2019-03-25 2020-03-23 Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb. MX2021011614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019079543 2019-03-25
PCT/EP2020/057937 WO2020193459A1 (en) 2019-03-25 2020-03-23 Solid forms of a compound of hbv core protein allosteric modifier

Publications (1)

Publication Number Publication Date
MX2021011614A true MX2021011614A (es) 2021-10-13

Family

ID=70005624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011614A MX2021011614A (es) 2019-03-25 2020-03-23 Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.

Country Status (12)

Country Link
US (2) US11873302B2 (es)
EP (1) EP3947383A1 (es)
JP (1) JP2022525522A (es)
KR (1) KR20210136078A (es)
CN (1) CN113614088A (es)
AU (1) AU2020249331A1 (es)
BR (1) BR112021019054A2 (es)
CA (1) CA3130596A1 (es)
IL (1) IL286599A (es)
MX (1) MX2021011614A (es)
TW (1) TW202102503A (es)
WO (1) WO2020193459A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061978B (zh) * 2014-03-07 2018-10-23 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
WO2005085462A1 (en) 2004-02-27 2005-09-15 Dsm Ip Assets B.V. Enzymatic preparation of an enantiomerically enriched beta-2-amino acids
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
CN101282965A (zh) 2005-09-22 2008-10-08 斯克利普斯研究院 基于烷氧基吲哚酮的蛋白激酶抑制剂
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
CN100453542C (zh) 2007-04-30 2009-01-21 广东东阳光药业有限公司 2-杂环取代的二氢嘧啶消旋化合物的拆分方法
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
ES2454366T3 (es) 2008-02-22 2014-04-10 Neurotune Ag Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico
CN103536906A (zh) 2008-06-05 2014-01-29 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎
JP5816087B2 (ja) 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体
WO2010069147A1 (zh) 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
PL2888241T3 (pl) 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
MX2015002954A (es) 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
CN105209470B (zh) 2013-05-17 2018-02-06 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶
CN104650069B (zh) 2013-11-19 2019-04-19 广东东阳光药业有限公司 4-甲基二氢嘧啶类化合物及其在药物中的应用
CN106061978B (zh) 2014-03-07 2018-10-23 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶
WO2016016196A1 (en) 2014-07-31 2016-02-04 F. Hoffmann-La Roche Ag Novel chiral resolution of 4-aryl-2-thiazol-2-yl-1,4-dihydropyrimidine-5-carboxylic acid esters
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
WO2016146598A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
AR107633A1 (es) 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
JP2019526562A (ja) 2016-08-24 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法
KR102497701B1 (ko) 2016-09-13 2023-02-09 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제의 병용 치료
US20220265817A1 (en) 2017-05-31 2022-08-25 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
US20190151307A1 (en) 2017-10-24 2019-05-23 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
JP2022535112A (ja) 2019-06-06 2022-08-04 エフ．ホフマン－ラ ロシュ アーゲー ４－フェニル－５－アルコキシカルボニル－２－チアゾール－２－イル－１，４－ジヒドロピリミジン－６－イル］メチル］－３－オキソ－５，６，８，８ａ－テトラヒドロ－１Ｈ－イミダゾ［１，５－ａ］ピラジン－２－イル］－カルボン酸を調製するための代替方法
JP2022548652A (ja) 2019-09-20 2022-11-21 エフ．ホフマン－ラ ロシュ アーゲー コアタンパク質アロステリックモジュレータを使用してｈｂｖ感染を処置する方法

Also Published As

Publication number Publication date
US20200308178A1 (en) 2020-10-01
US20240116941A1 (en) 2024-04-11
US11873302B2 (en) 2024-01-16
TW202102503A (zh) 2021-01-16
AU2020249331A1 (en) 2021-09-23
CA3130596A1 (en) 2020-10-01
EP3947383A1 (en) 2022-02-09
JP2022525522A (ja) 2022-05-17
WO2020193459A1 (en) 2020-10-01
KR20210136078A (ko) 2021-11-16
BR112021019054A2 (pt) 2021-11-30
IL286599A (en) 2021-10-31
CN113614088A (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
JP6668468B2 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12021551116A1 (en) Functionalized heterocycles as antiviral agents
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
JP2018531272A6 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
PE20211647A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb
RU2012104993A (ru) Тритерпеновые производные лупеольного типа как противовирусные препараты
RU2004132203A (ru) Индолилмалеимидные производные
MX2020002191A (es) Agentes antivirales contra la hepatitis b.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
RU2010112450A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
MY186986A (en) Compositions and methods of use of phorbol esters
EA200702384A1 (ru) Лечение заболеваний печени, в патогенезе которых задействовано железо
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
MX2021003253A (es) Heterociclos funcionalizados como agentes antivirales.
WO2009036341A3 (en) Compositions and methods relating to hiv protease inhibition
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
PH12021551232A1 (en) Haloallylamine compounds and application thereof
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
MX2022002331A (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].
US11191754B2 (en) Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor